Navigation Links
Adeona's Clinical Study of reaZin™ Meets Primary Outcomes of Increasing Serum Zinc and Decreasing Serum Free Copper
Date:4/14/2011

primary outcome with the statistically significant change in the free copper to zinc ratio in the treatment group over the placebo group," stated George J. Brewer, M.D., Adeona's Senior Vice President of Research & Development. "Also, of ultimate importance with respect to a potential treatment for Alzheimer's disease patients, the composite score supports cognitive benefit in the treatment group versus the placebo group."

Dr. Pollock also commented on the clinical study, "In my clinical experience, this zinc therapy appears to have been extremely well tolerated and may represent a new mechanism of action to address the cognitive deficits in Alzheimer's patients. This potential treatment deserves further study in larger clinical trials."

"Based on the favorable results presented from this clinical study, we intend to further the commercial development of reaZin as a prescription medical food for the dietary management of Alzheimer's disease and mild cognitive impairment," stated James S. Kuo, M.D., M.B.A., Adeona's Chief Executive Officer. "In addition, we will be reviewing the results from our clinical study with our scientific advisors to determine what further clinical studies might be warranted to support additional labeling claims."

About Adeona Conference Call/Audio Webcast

Adeona will hold a conference call/audio webcast to discuss the results from the clinical study evaluating reaZin for the dietary management of Alzheimer's disease and mild cognitive impairment on Friday, April 15, 2011, at 8:00 a.m. (HAST)/2:00 p.m. (EDT). James S. Kuo, M.D., M.B.A., Adeona's Chief Executive Officer and Diana Pollock, M.D., Lead Principal Investigator of the study at Morton Plant Neuroscience Institute on the campus of Morton Plant Hospital, will host the call. Interested parties should call toll free 1-800-860-2442 (U.S.) or 1-866-605-3852 (Canada), or from outside North America +1 412-858-4600, fifteen minutes b
'/>"/>

SOURCE Adeona Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. PharmAthene Completes Dosing in Valortim® Phase I Clinical Trial
2. New Clinical Studies Reinforce the LAP-BAND® System is a Safe and Effective Weight-Loss Treatment for Obese Adults with Obesity-Related Comorbid Conditions
3. GE Healthcare Presents Interim Data on the Impact of DaTscan™ (Ioflupane I 123 Injection) SPECT Imaging on the Diagnosis and Clinical Management of Patients with Clinically Uncertain Parkinsonian Syndrome
4. Visual Healthcare to Support Chinese Clinical Trials
5. Preclinical Studies in Pancreatic Cancer and Melanoma Demonstrated ADI-PEG 20 Works Synergistically With Inhibitors of Autophagy
6. Spaulding Clinical Welcomes Dr. Aziz Karim, Clinical Pharmacokinetic Consultant
7. Vanda Pharmaceuticals Announces Commencement of Clinical Study of Long-Acting Injectable Formulation of Fanapt®
8. Update on Phase II/III Clinical Trial of Investigational Staphylococcus aureus Vaccine, V710
9. Regeneron and Bayer Announce Start of Phase 3 Clinical Program in Diabetic Macular Edema
10. Hospira Reinforces Importance of Clinical Surveillance Technology in Line With World Health Day Focus on Antimicrobial Resistance
11. Boston Scientific Begins International Clinical Trial Enrollment for INNOVA™ Self-Expanding Bare-Metal Stent System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... Sept. 22, 2014 The western European ... It is largely a replacement market with fewer ... mergers, acquisitions and partnerships are redefining competitive landscape ... research service provides details about revenue forecasts, unit ... trends across the country. The changing landscape makes ...
(Date:9/22/2014)... , September 22, 2014 ... September 25   The second edition of ... are excited to announce the final nominations for the ... announced on the evening of September 25 at The Taj Mahal Palace, ... from applicants based on a variety of qualitative and ...
(Date:9/22/2014)... , Sept. 22, 2014  Elusys Therapeutics, Inc. ... treat infectious disease, today announced it has completed ... of obiltoxaximab (ETI-204). Obiltoxaximab is an anti-toxin in ... data from these studies support the safety and ... at the intended therapeutic dose. The conclusion of ...
Breaking Medicine Technology:Automated Endoscope Reprocessor Market Trends in Western Europe 2Automated Endoscope Reprocessor Market Trends in Western Europe 3Recognising Impactful Healthcare Companies at VCCircle Healthcare Awards 2014 2Recognising Impactful Healthcare Companies at VCCircle Healthcare Awards 2014 3Elusys Announces Results From Three Phase 3 Safety Studies Of Its Anthrax Anti-Toxin, Obiltoxaximab (ETI-204), In Adult Volunteers And Completion Of Its Phase 3 Clinical Development Program 2Elusys Announces Results From Three Phase 3 Safety Studies Of Its Anthrax Anti-Toxin, Obiltoxaximab (ETI-204), In Adult Volunteers And Completion Of Its Phase 3 Clinical Development Program 3Elusys Announces Results From Three Phase 3 Safety Studies Of Its Anthrax Anti-Toxin, Obiltoxaximab (ETI-204), In Adult Volunteers And Completion Of Its Phase 3 Clinical Development Program 4Elusys Announces Results From Three Phase 3 Safety Studies Of Its Anthrax Anti-Toxin, Obiltoxaximab (ETI-204), In Adult Volunteers And Completion Of Its Phase 3 Clinical Development Program 5Elusys Announces Results From Three Phase 3 Safety Studies Of Its Anthrax Anti-Toxin, Obiltoxaximab (ETI-204), In Adult Volunteers And Completion Of Its Phase 3 Clinical Development Program 6
... Council,joins organizations and individuals across the country and around ... December 1, 2007. Since 1988,World AIDS Day has provided ... to reinvigorate global, national, regional,and local efforts to stop ... AIDS Day is leadership. Nearly 27,years since it was ...
... Results Also Show Potentially Differentiating Pharmacokinetic ... ... Shire plc (LSE: SHP,Nasdaq: SHPGY, TSX: SHQ), the global ... results of a study,showing VYVANSE(TM) (lisdexamfetamine dimesylate), the first ...
Cached Medicine Technology:AIDS Action Council Statement on World AIDS Day 2007: Leadership Needed for a National Strategy to Stop the AIDS Epidemic 2Biological Psychiatry Publishes Study Showing VYVANSE Demonstrated Significant Efficacy for Treatment of ADHD for up to 12 Hours After Administration 2Biological Psychiatry Publishes Study Showing VYVANSE Demonstrated Significant Efficacy for Treatment of ADHD for up to 12 Hours After Administration 3Biological Psychiatry Publishes Study Showing VYVANSE Demonstrated Significant Efficacy for Treatment of ADHD for up to 12 Hours After Administration 4Biological Psychiatry Publishes Study Showing VYVANSE Demonstrated Significant Efficacy for Treatment of ADHD for up to 12 Hours After Administration 5Biological Psychiatry Publishes Study Showing VYVANSE Demonstrated Significant Efficacy for Treatment of ADHD for up to 12 Hours After Administration 6
(Date:9/23/2014)... driving force behind many chronic diseases, especially liver ... caused by conditions such as viral hepatitis or ... Now, scientists at Virginia Commonwealth University Massey Cancer ... preclinical studies that blocking the expression of a ... the development and progression of liver cancer by ...
(Date:9/23/2014)... (PRWEB) September 23, 2014 Becker's ... its list of "125 Hospitals and Health Systems ... health systems featured on the list have orthopedic ... earned recognition from several reputable sources. Exceptional orthopedic ... patients, front-line orthopedic research and treat professional athletes. ...
(Date:9/23/2014)... 2014 The "area under the curve of oxygen ... approach to monitoring blood oxygen levels during procedures using ... & Analgesia . , The AUC Desat provides ... lowbut also on the depth, duration, and rate of ... Paul Niklewski, PhD, of University of Cincinnati and colleagues ...
(Date:9/23/2014)... Contrary to what is often assumed about single parents, ... from The Kinsey Institute has found that single parents ... active as often as singles without children -- and ... The study, "Dating and Sexual Behavior Among Single Parents ... online in the Journal of Sex Research ...
(Date:9/23/2014)... September 23, 2014 Kenall Manufacturing, ... expanded its MedMaster™ M4 product line with a ... the M4 product line – currently available with ... – providing more flexibility when designing lighting for ... MedMaster M4 Series include:, •Three sizes available ...
Breaking Medicine News(10 mins):Health News:Study uncovers genetic driver of inflammation, uses it to prevent and treat liver cancer 2Health News:125 Hospitals With Great Orthopedic Programs 2Health News:125 Hospitals With Great Orthopedic Programs 3Health News:125 Hospitals With Great Orthopedic Programs 4Health News:125 Hospitals With Great Orthopedic Programs 5Health News:New measure provides more data on oxygen levels during sedation 2Health News:Kinsey study of single parents' dating, sexual activity contradicts assumptions 2Health News:Kenall Expands MedMaster™ M4 Surgical Suite Product Portfolio with New 1'×4' Option 2Health News:Kenall Expands MedMaster™ M4 Surgical Suite Product Portfolio with New 1'×4' Option 3
... don,t let love interfere with your work, researchers say , ... who found your Valentine at work, here,s good news. , ... negative effect, a new Canadian study finds. , "Most people ... they don,t affect productivity, de-motivate other colleagues or have an ...
... ... Toppers feature 100% Natural Dunlop Latex for an affordable 100% natural latex mattress or ... organic Eco Wool batting, creating an organic latex mattress, free from chemical fire-retardants. ... (PRWEB) February 14, ...
... ... practitioner now seeing patients in the River Walk Medical Arts Building. , ... (PRWEB) February 14, 2010 -- Elias Medical recently ... office is located within the River Walk Medical Arts Building at 9900 Stockdale Highway, adjacent ...
... , LOS ANGELES , ... today by Consumer Watchdog -- Anthem Blue Cross,s announcement today that ... or more should not deter the California Legislature from taking immediate ... Other California health insurers -- including Blue Shield of ...
... Feb. 13 The beauty of budding plants and ... allergy sufferers, though, gardening can be as much a chore as ... cause an onslaught of allergy symptoms, including sneezing, itchy eyes, congestion ... can take a few simple steps to minimize their risk of ...
... Compassion appeared to be contagious in experiment using volunteers ... do a good deed appears to inspire you to do ... , In an experiment, researchers recruited volunteers who watched a ... a clip from "The Oprah Winfrey Show" in which musicians ...
Cached Medicine News:Health News:Office Romance OK With Most Folks 2Health News:Foamsource Introduces Natural Slumber 100% Natural Latex Mattresses & Toppers with Free Shipping 2Health News:Foamsource Introduces Natural Slumber 100% Natural Latex Mattresses & Toppers with Free Shipping 3Health News:Elias Medical Announces Move to New Stockdale Highway Practice 2Health News:Anthem Blue Cross's Announcement That It Will Temporarily Suspend a 39% Health Insurance Rate Increase Should Not Deter Immediate Legislative Action 2Health News:Avoid Allergens to Reap the Rewards of Gardening 2Health News:Avoid Allergens to Reap the Rewards of Gardening 3Health News:Witnessing Uplifting Behavior May Spur Good Deeds 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: